WithdrawnNot Applicable

Genicular Artery Embolization (GAE) for Osteoarthritic Knee Pain

Stopped: No Insurance Coverage

United States0Started 2025-01-15

Plain-language summary

The objective of this investigation is to evaluate the safety of the geniculate artery embolization (GAE) procedure with HydroPearl® Microspheres in 30 patients with knee pain caused by osteoarthritis with 24 months follow-up. The GAE procedure is an arterial embolization procedure that blocks abnormal blood vessels caused be knee arthritis in order to evaluate the effect on knee pain.

Who can participate

Age range

40 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Provide informed consent
. Age ≥ 40 years
. Moderate to severe knee pain (VAS \>40 mm)
. Pain refractory to 3 months of conservative treatments, including at least one of the following:
. Kellgren-Lawrence radiographic grade 1, 2, or 3 disease
. MRI features of active synovitis (synovial thickening and/or enhancement on MRI).
. Ineligibility or refusal of surgical management.
. Local knee tenderness

Exclusion criteria

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of patients with treatment related adverse events

Timeframe: 1 month post GAE

Number of patients with treatment related adverse events

Timeframe: 6 months post GAE

Number of patients with treatment related adverse events

Timeframe: 12 months post GAE

Number of patients with treatment related adverse events

Timeframe: 24 months post GAE

Trial details

NCT IDNCT04472091

SponsorAndrew Picel

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-11-01

View on ClinicalTrials.gov More Knee Osteoarthritis trials

Plain-language summary

Who can participate

Age range

40 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Provide informed consent
. Age ≥ 40 years
. Moderate to severe knee pain (VAS \>40 mm)
. Pain refractory to 3 months of conservative treatments, including at least one of the following:
. Kellgren-Lawrence radiographic grade 1, 2, or 3 disease
. MRI features of active synovitis (synovial thickening and/or enhancement on MRI).
. Ineligibility or refusal of surgical management.
. Local knee tenderness

Exclusion criteria

What they're measuring

Number of patients with treatment related adverse events

Timeframe: 1 month post GAE

Number of patients with treatment related adverse events

Timeframe: 6 months post GAE

Number of patients with treatment related adverse events

Timeframe: 12 months post GAE

Number of patients with treatment related adverse events

Timeframe: 24 months post GAE